National Bank of Canada
FBRX icon

National Bank of Canada’s Forte Biosciences FBRX Stock Holding History

National Bank of Canada’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4K Buy
478
+402
+529% +$11.6K ﹤0.01% 2282
2025
Q4 		$2.07K Buy
+76
New +$1.33K ﹤0.01% 2559

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

National Bank of Canada's FBRX Position: Q1 2026 in Review

National Bank of Canada increased its Forte Biosciences (FBRX) stake by 529% in Q1 2026, buying an estimated $11.6K and bringing the position to 478 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2282.

National Bank of Canada first reported a position in FBRX in Q4 2025 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • National Bank of Canada held 478 shares of Forte Biosciences worth $12.4K as of Q1 2026.
  • National Bank of Canada bought 402 Forte Biosciences shares in Q1 2026, an estimated $11.6K.
  • Forte Biosciences made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2282 holding.
  • National Bank of Canada first reported a position in Forte Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.